• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

    42.02 -0.84 (-1.95%)
    Streaming Delayed Price Updated: 12:44 PM EDT, May 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about TG Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    News headline image
    Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
    This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
    Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology. 
    Via The Motley Fool
    TG THERAPEUTICS INC (NASDAQ:TGTX) Screens as Affordable Growth Play with Strong Revenue Surge and Discounted Valuation ↗
    Via Chartmill
    News headline image
    TG Therapeutics (TGTX) Q1 2026 Earnings Transcript ↗
    TG Therapeutics (TGTX) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    TG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Beat Revenue Guidance but Miss EPS Estimates ↗
    Via Chartmill
    Topics Earnings
    TG Therapeutics Inc (NASDAQ:TGTX) Shows Strong Growth and Technical Setup for Potential Upside ↗
    Via Chartmill
    News headline image
    TGTX Q1 2025 Earnings Call Transcript ↗
    TGTX Q1 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum ↗
    Via Chartmill
    News headline image
    What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
    Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗
    This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology. 
    Via The Motley Fool
    TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup ↗
    Via Chartmill
    TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook ↗
    Via Chartmill
    Topics Earnings
    TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally ↗
    Via Stocktwits
    News headline image
    TG Therapeutics (TGTX) Q4 2025 Earnings Transcript ↗
    TG Therapeutics (TGTX) Q4 2025 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Soleus Adds a Significant Number of Celcuity Shares ↗
    This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment. 
    Via The Motley Fool
    News headline image
    TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win' ↗
    TG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression. 
    Via Stocktwits
    News headline image
    Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares ↗
    This commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse clinical pipeline. 
    Via The Motley Fool
    TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For November 3, 2025 ↗
     
    Via Benzinga
    News headline image
    Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? ↗
    On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI. 
    Via Stocktwits
    Topics Artificial Intelligence
    News headline image
    TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 ↗
    The company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S. 
    Via Stocktwits
    Topics Artificial Intelligence
    These stocks are moving in today's after hours session ↗
    Via Chartmill
    News headline image
    TG Therapeutics TGTX Q3 2025 Earnings Transcript ↗
    TG Therapeutics TGTX Q3 2025 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Earnings Preview For TG Therapeutics ↗
     
    Via Benzinga
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
     
    Via Benzinga
    News headline image
    TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗
    Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics. 
    Via Investor's Business Daily
    News headline image
    Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million ↗
    Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million 
    Via The Motley Fool
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
     
    Via Benzinga
    News headline image
    Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
    Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. 
    Via Benzinga
    News headline image
    Highly Watched TG Therapeutics Smashes Profit Views — With A Caveat ↗
    TG Therapeutics stock rose early Monday on better-than-expected earnings. 
    Via Investor's Business Daily
    Topics Earnings
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.